Maneesh Paul. S., M. Sc., Ph.D., FIDSA.,
Bengaluru, Karnataka, India
4K followers
500+ connections
About
A Techno-commercial Enabler, Influencer, Intrapreneur & a Biologist with broad…
Articles by Maneesh
-
My journey to becoming a Microbiologist
My journey to becoming a Microbiologist
By Maneesh Paul. S., M. Sc., Ph.D., FIDSA.,
Contributions
Activity
-
✨Dr. Maneesh Paul. S., M. Sc., Ph.D., FIDSA., Co-inventor of Enmetazobactam, CEO of Microvioma, will be a panelist at the 10th IPHEX Conference in…
✨Dr. Maneesh Paul. S., M. Sc., Ph.D., FIDSA., Co-inventor of Enmetazobactam, CEO of Microvioma, will be a panelist at the 10th IPHEX Conference in…
Liked by Maneesh Paul. S., M. Sc., Ph.D., FIDSA.,
-
✨LATEST STUDY✨ Gut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders 🚨 In recent years, gut microbiome…
✨LATEST STUDY✨ Gut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders 🚨 In recent years, gut microbiome…
Liked by Maneesh Paul. S., M. Sc., Ph.D., FIDSA.,
-
Meet our excellent line-up of speakers🎙: Dr. Renuka Thergaonkar, Director, R&D Global Consultants Dr. Maneesh Paul. S., M. Sc., Ph.D., FIDSA.…
Meet our excellent line-up of speakers🎙: Dr. Renuka Thergaonkar, Director, R&D Global Consultants Dr. Maneesh Paul. S., M. Sc., Ph.D., FIDSA.…
Liked by Maneesh Paul. S., M. Sc., Ph.D., FIDSA.,
Experience
Education
-
Multiple Institutes over a period
Medicinal Chemistry & New Drug Discovery at Biocon Academy, ACS, IUPAC (USA) India, 2019
Health Research Methodology & Evidence Based medicine at St. Johns Research Institute & Mc Master University, Canada, India in 2015
Clinical Trial Audit at St. Johns Research Institute, India in 2014
NABL ISO 15189 – 2012 Audit & QMS at FQI, India in 2013
OMGR-A Safety at Orchid, India-DuPont USA, in 2011
Clinical Trials at CMC Vellore, India in 2011
Green Management at ER Company, USA in…Medicinal Chemistry & New Drug Discovery at Biocon Academy, ACS, IUPAC (USA) India, 2019
Health Research Methodology & Evidence Based medicine at St. Johns Research Institute & Mc Master University, Canada, India in 2015
Clinical Trial Audit at St. Johns Research Institute, India in 2014
NABL ISO 15189 – 2012 Audit & QMS at FQI, India in 2013
OMGR-A Safety at Orchid, India-DuPont USA, in 2011
Clinical Trials at CMC Vellore, India in 2011
Green Management at ER Company, USA in 2011
Drug Design & Discovery at Bioinformatics Institute of India, India in 2006
Data Security at NIH, USA in 2005
Reviewer in Regulatory Process at US FDA, USA in 2005
Basic GLP standards at NIH, USA in 2005
Mice infection & Bleeding, at NIH, USA in 2005
Rat handling at NIH, USA in 2005
Rodent handling at Johns Hopkins Medical Institutes, USA in 2004
Microbial Pathogenesis at Umeå Univ. Sweden in 2002
Protein Purification at Umeå Univ. Sweden in 2002
Unix & Basic C, LCC, at India in 1999 -
-
Thesis work was done with Scientific support from Dr. J C Lee of The Channing Laboratory, Harvard Medical School, Boston USA.
I was the first from India to study and report the prevalence of Capsular Polysaccharide types expressed in Staphylococcus aureus in India. -
-
This Course was completed as a Distance education while pursuing doctoral studies.
-
-
Under the Faculty of Medicine from Kasturba Medical College, Mangalore
During my Masters I reported the first case of Yersinia pseudotuberculosis induced diarrhoea from India (in Tropical Doctor). -
-
-
-
-
-
-
-
-
OTHER TECHNICAL TRAINING
Curli molecular biology at Washington University, St. Louis, USA in 2002
MSMS evaluation of Curli at Karolinska Institute, Stockholm Sweden in 2002
Basics of Proteomics at Univ Central Hospital, Helsinki, Finland in 2002
Bacteriophage typing at Maulana Azad Medical College, ND, India in 1999
Techniques in Mycobacterium leprae at SLRTC, Karigiri, India in 1995
Publications
-
My Publications
Peer-reviewed
All my publications are at this link along with the Citation index: http://scholar.google.co.in/citations?user=9v48-88AAAAJ&hl=en&oi=sra
PubMed Keywords: <Paul-satyaseela OR Maneesh PS>
Patents
-
Carbapenem Compounds
Filed US WO2017158616A1
Abstract
This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infectionOther inventorsSee patent -
Compounds and their use
Issued US US20140057888A1,
Abstract
WO2012070071A1, US20140057888A1, JP5961177B2, KR20140052927A, CN103347515B, CA2818100A1, EP2642992A1
Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as β -lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable…Abstract
WO2012070071A1, US20140057888A1, JP5961177B2, KR20140052927A, CN103347515B, CA2818100A1, EP2642992A1
Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as β -lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable antibiotic agent. The compounds of formula (I) act as inhibitors of β-lactamases. These compounds restore/potentiate the activities of β-lactam antibiotics against carbapenemases. These compounds find use in diagnostic method for detecting β-lactamases. Formula (I)Other inventorsSee patent -
Histone deacetylase inhibitors for the treatment of fungal infections
Issued US WO2011058582A1
Abstract
Described are bridged compounds of the formula (I), their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The invention relates to compositions and methods to treat fungal infection. These compounds are selective HDAC inhibitors that act as inherent antifungal compounds or enhance the activity of other antifungal compounds such as azolesOther inventorsSee patent -
2-substituted methyl penam derivatives
Issued US US7687488B2
Abstract
Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them;
Figure US07687488-20100330-C00001
wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or —COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a…Abstract
Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them;
Figure US07687488-20100330-C00001
wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or —COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted alkyl, alkenyl, alkynyl and the like; R represents substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heterocyclylalkyl.Other inventorsSee patent -
Novel compounds and their use
US WO 2009/001192
The present invention provides novel compounds, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The novel compounds are useful as antibacterial agents in the treatment of conditions such as nosocomial pneumonia, community acquired pneumonia, infections caused by vancomycin resistant enterococci (VRE), methicillin resistant Staphylococcus aureus (MRSA), Heamophilus…
The present invention provides novel compounds, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The novel compounds are useful as antibacterial agents in the treatment of conditions such as nosocomial pneumonia, community acquired pneumonia, infections caused by vancomycin resistant enterococci (VRE), methicillin resistant Staphylococcus aureus (MRSA), Heamophilus influenzae (HI) and penicillin resistant Streptococcus pneumoniae (PRSP). The compounds of the present invention are effective against a number of human or animal pathogens including VRE, PRSP, HI and MRSA.
Other inventors
Languages
-
Kannada
-
-
Hindi
-
-
Swedish
-
-
Telugu
-
-
English
Native or bilingual proficiency
Organizations
-
Royal Society for Public Health
-
- PresentAccorded the qualification of FRSPH since 2023
-
British Society for Antimicrobial Chemotherapy
Member
- Present -
European Society of Clinical Microbiology and Infectious Diseases
Member
- Present -
Infectious Diseases Society of America, Arlington, VA, USA
Member
- PresentNominated as the member of the "IDSA Research Committee Advisory Group" for this Academic year 2017-18 on the 11-member committee.
-
American Society for Microbiology
Member
- Present -
FELLOW OF ACADEMY OF GRADUATE EDUCATION
Member
- Present
Recommendations received
7 people have recommended Maneesh
Join now to viewMore activity by Maneesh
-
Join us at the Global Bio India Roadshow 2024! 🌿 Get ready to be inspired by the future of biotechnology in India. This exciting event will feature…
Join us at the Global Bio India Roadshow 2024! 🌿 Get ready to be inspired by the future of biotechnology in India. This exciting event will feature…
Liked by Maneesh Paul. S., M. Sc., Ph.D., FIDSA.,
-
It's with great honour that I salute my dear sister Matshidiso Moeti, who is ending her term as WHO Africa Regional Director after 10 years of…
It's with great honour that I salute my dear sister Matshidiso Moeti, who is ending her term as WHO Africa Regional Director after 10 years of…
Liked by Maneesh Paul. S., M. Sc., Ph.D., FIDSA.,
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More